Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV

AIDS

Volumn 30, Issue 5, 2016, Pages 797-801

  Den Boon, Saskia ^a   Matteelli, Alberto ^b   Ford, Nathan ^b   Getahun, Haileyesus ^b  

^a Independent consultant   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

antiretroviral therapy; chemoprophylaxis; HIV AIDS; isoniazid; prevention; re infection; tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BOTSWANA; DATA BASE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; LATENT TUBERCULOSIS; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIDE EFFECT; SOUTH AFRICA; SPUTUM SMEAR; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULIN TEST; COMPLICATION; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; BOTSWANA; HIV INFECTIONS; HUMANS; INDIA; ISONIAZID; LATENT TUBERCULOSIS; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84963682933     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000985     Document Type: Article

References (13)

1. World Health Organization (WHO). Guidelines for intensified case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO; 2011
2. Tuberculosis preventive therapy in HIV-infected individuals. A Joint Statement of the WHO and IUATLD. Wkly Epidemiol Rec 1993; 68: 361-364
3. Getahun H, Matteelli A, Chaisson RE, Raviglioni M. Latent Mycobacterium tuberculosis Infection. N Engl J Med 2015; 372: 2127-2135
4. Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci USA 2014; 111: 5325-5330
5. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse and reinfection of tuberculosis after cure: a cohort in South African mineworkers. Lancet 2001; 358: 1687-1693
6. World Health Organization. Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB-And HIV-prevalence settings-2015 update. Geneva, Switzerland: WHO; 2015
7. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598
8. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20
9. Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One 2012; 7: e47400
10. Schulz KF, Chalmers I, Hayes RJ, Altman DG, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412
11. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind placebo-controlled trial. Lancet 2014; 384: 682-690
12. Golub JE, Cohn S1, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. Long-Term Protection From Isoniazid Preventive Therapy for Tuberculosis in HIV-Infected Patients in a Medium-Burden Tuberculosis Setting: The TB/HIV in Rio (THRio) Study. Clin Infect Dis 2015; 60: 639-645
13. Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile OI, et al. Tuberculosis incidence increase after 36 months isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS 2015; 29: 351-359